Of the four patients with advanced NF1-mutant lung adenocarcinoma in poor performance status, only one achieved disease stability after third-line trametinib treatment, which may be related to an allele mutation. Further expanded MAPK gene screening is needed. — MedSci

Full Article Content

{{ if item. readStatus! = 1 }} {{/if}} {{ if item. readStatus == 1 }} {{/if}} {{ if item. hrefUrl }} {{item. messageTitle}} {{else}} {{item. messageTitle}} {{/if}} {{ if item. hrefUrl || item. messageContent. length < 60 }} Expand {{else}} Expand {{/if}} Collapse {{ if item. hrefUrl }} {{item. messageContent}} {{else}} {{item. messageContent}} {{/if}} {{ item. cardName }} {{if item. expired}} Expired {{else}} {{ item. endTime. split(' ') }}Expired {{/if}} {{if item. expired}} {{else}} {{if item. propertyName == 'Course Membership'}} {{else}} {{/if}} {{/if}} {{if item. expired}} {{else}} {{/if}}